|
2015 Conference Publication Experiences of Uncertainty and Invisibility: Women's Accounts of Living with a Rare CancerWyld, David, Gibson, Alexandra, Broom, Alex, Plage, Stefanie, Cubitt, Annette and Lwin, Zarnie (2015). Experiences of Uncertainty and Invisibility: Women's Accounts of Living with a Rare Cancer. COSA’s 42nd Annual Scientific Meeting. Rare Cancers, Hobart, TAS, Australia, 17-19 November 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.12432_2 |
|
2015 Conference Publication A Phase II Study of Everolimus in patients with FDG-PET positive intermediate grade (Ki67 3-20%) pancreatic neuroendocrine tumorMichael, M., Pavlakis, N., Wyld, D., Link, E., Liauw, W., Kuru, N. and Hicks, R. (2015). A Phase II Study of Everolimus in patients with FDG-PET positive intermediate grade (Ki67 3-20%) pancreatic neuroendocrine tumor. 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, March 11-13, 2015. Basel, Switzerland: S. Karger AG. doi: 10.1159/000431385 |
|
2015 Conference Publication A case of pulmonary carcinoid in pregnancy and review of carcinoid tumours in pregnancyKevat, D., Chen, M., Wyld, D., Fagermo, N. and Lust, K. (2015). A case of pulmonary carcinoid in pregnancy and review of carcinoid tumours in pregnancy. RCOG World Congress 2015, 12–15 April, Brisbane, Queensland, Australia, Brisbane, Queensland, Australia, 12–15 April 2015. Chichester, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/1471-0528.13370 |
|
2015 Conference Publication Patient understanding of research in a medical oncology settingRoberts, Natasha, Ives, Amy, Wyld, David and Cubitt, Annette (2015). Patient understanding of research in a medical oncology setting. COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, Australia, 17–19 November 2015. Chichester, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.12432_2 |
|
2015 Conference Publication Efficacy of PRRT in metastatic neuroendocrine tumors; a retrospective large single institutional studyJan, H., Wyld, D. and Burge, M. (2015). Efficacy of PRRT in metastatic neuroendocrine tumors; a retrospective large single institutional study. 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 11-13, 2015. Basel, Switzerland: S. Karger AG. doi: 10.1159/000431385 |
|
2014 Conference Publication Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyraponeChan, B. A., Wyld, D., Burge, M., Cuneo, R., Macfarlane, D. and Lee, K. (2014). Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyrapone. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG. |
|
2014 Conference Publication Locally advanced and metastatic pancreatic cancer: an assessment of the provision of chemotherapy at a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Locally advanced and metastatic pancreatic cancer: an assessment of the provision of chemotherapy at a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATELee, K., Conway, L., Burge, M., Wyld, D. and Macfarlane, D. (2014). Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATE. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG. |
|
2014 Conference Publication Assessment of time to commencement of neoadjuvant long course chemoradiotherapy (Lccrt) for locally advanced rectal adenocarcinoma patients in a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Assessment of time to commencement of neoadjuvant long course chemoradiotherapy (Lccrt) for locally advanced rectal adenocarcinoma patients in a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (Lccrt) for metropolitan versus rural patients referred to a Queensland tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (Lccrt) for metropolitan versus rural patients referred to a Queensland tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Rural Oncology Care Via Teleoncology and Outreach Clinics: Patient and Staff Perspectives and ComparisonsWyeth, Holly, Chan, Bryan, Burge, Matthew, Wyld, David and Eastgate, Melissa (2014). Rural Oncology Care Via Teleoncology and Outreach Clinics: Patient and Staff Perspectives and Comparisons. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, VIC Australia, 2-4 December 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2013 Conference Publication Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needsBeesley, Vanessa L., Janda, Monika, Wockner, Leesa F., O'Rourke, Peter, Gooden, Helen, Goldstein, David, Merrett, Neil D., Wyld, David K. and Neale, Rachel E. (2013). Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age, Adelaide Convention Centre, Adelaide, SA Australia, 12-14 November 2013. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2012 Conference Publication Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus IncidentalThaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL. |
|
2012 Conference Publication Usefulness of medical oncologists' estimates of survival time in people with advanced cancerKiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology. |
|
2012 Conference Publication Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, kShapiro, Jeremy David, Siu, Lillian L., O'Callaghan. Christopher J., Zalcberg, John Raymond, Moore, Malcolm J., Price, Timothy Jay, Doyle, Catherine, Simes, John, Findlay, Brian Peter, Cronk, Michelle F., Shaikh, Asif, Joubert, Warren Lance, Samson, Benoit, Bonaventura, Antonino, Underhill, Craig, Wyld, David, Walters, Ian B., Phillips, Penny, Tu, Dongsheng and Jonker, Derek J. (2012). Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k. 2012 ASCO Annual Meeting, Chicago Il, United States, 01-05 June 2012. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2012 Conference Publication Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's HospitalSharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2012 Conference Publication Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancerDzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing. |
|
2011 Conference Publication Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective studyBurge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom. |
